Investigator barriers and preferences to conduct clinical drug trials in Finland: a qualitative study

Author： Keinonen T. Keränen T. Klaukka T. Saano V. Ylitalo P. Enlund H.

ISSN： 0928-1231

Source： Pharmacy World and Science, Vol.25, Iss.6, 2003-12, pp. : 251-259

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Trials and the Independence of Investigators: A Novel Method for the Conduct of Pharmaceutical Company-Funded Clinical Drug Trials Which Ensures Investigator Independence

By Beran Roy G. Ainley Laetitia A.E. Beran Maureen E.

International Journal of Pharmaceutical Medicine, Vol. 19, Iss. 5-6, 2005-01 ,pp. : 309-316

Adis International

Access to resources Recommend Favorite

Post-Launch Clinical Investigator Drug Prescribing in the US: The Behaviour of Clinical Trial Investigators after Participating in Phase III Trials

By Glass Harold E. Rosenthal Bruce

International Journal of Pharmaceutical Medicine, Vol. 19, Iss. 2, 2005-01 ,pp. : 97-104

Adis International

Access to resources Recommend Favorite

The contemporary situation for the conduct of clinical trials in Asia

By CG F. E W. D Z.

International Journal of Pharmaceutical Medicine, Vol. 15, Iss. 4, 2001-08 ,pp. : 169-173

Adis International

Access to resources Recommend Favorite

Clinical reasoning, clinical trials and risky drinkers in everyday primary care: A qualitative study of British general practitioners

By May Carl Rapley Tim Kaner Eileen

Addiction Research and Theory, Vol. 14, Iss. 4, 2006-08 ,pp. : 387-397

Informa Healthcare

Access to resources Recommend Favorite

It appears that few drug companies are willing to conduct trials in paediatric patients voluntarily

Inpharma, Vol. 1, Iss. 1239, 2000-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite